Optogenetics is a field of research that involves using light to control cells within living tissues, typically neurons. Optogenetic technologies have gained prominence in neuroscience and related fields, allowing researchers to selectively activate or inhibit specific cells with high precision.
Latest Optogenetics Companies Update
March 2023: Science, a biotechnology startup, has introduced a novel platform designed to streamline the process of medical device development and production for other organizations. Providing access to over eighty of Science's tools and services, including its thin-film electrode technologies, the Science Foundry platform enables organizations to leverage and expand upon Science's internal infrastructure. Developing medical devices frequently renders "prohibitive" the financial investment for nascent enterprises. There exists a prodigious cohort of individuals possessing a multitude of ideas that diverge significantly from those held by the organization, and they are inclined to empower them. The expanding brain-computer interface (BCI) sector includes science. A BCI is a system that translates commands for external technologies from deciphered brain signals.
May 2023: Ray Therapeutics, an optogenetics startup established in 2021, disclosed a $100 million Series A funding round in May 2023. The round was led by Novo Holdings A/S. Multiple programs that target debilitating eye diseases will advance through clinical development with the assistance of the funding. Ray's principal candidate for retinitis pigmentosa, a degenerative retinal disease, is RTx-015. It is imminently anticipated to undergo clinical trial testing. Retinitis pigmentosa and other hereditary retinal degenerations patients who presently have limited or no treatment options may find RTx-015 to be an encouraging development, as it has demonstrated remarkable efficacy in preclinical research. The utilization of optogenetics in these innovative treatments has the potential to substantially enhance the quality of life for those afflicted with blinding disorders. Deerfield Management, Norwest Venture Partners, Platanus, MRL Ventures Fund, the corporate venture fund of Merck & Co., Inc. focused on therapeutics, and existing investor 4BIO Capital joined the funding series.
Optogenetics Market Highlights:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)